Sean Johnson

Mr. Sean Johnson


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 August 2024 in Blood
Verified
Journal Article
Closed access
PDF file
JOJad Othman
Jad Othman
NPNicola Potter
Nicola Potter
AIAdam Ivey
Adam Ivey
YTYanis Tazi
Yanis Tazi
EPElli Papaemmanuil
Elli Papaemmanuil
RDRichard James Dillon
Richard James Dillon
Although NPM1-mutated acute myeloid leukemia (AML) carries a generally favorable prognosis, many patients still relapse and die. Previous studies identified several molecular and clinical features associated with poor outcomes; however, only FLT3-internal tandem duplication (ITD) mutation and adverse karyotype are currently used for risk stratification because of inconsistent results and uncertainty about how other factors should influence treatment, particularly given the strong prognostic effect of postinduction measurable residual disease (MRD). Here, we analyzed a large group of patients with NPM1 mutations (NPM1mut) AML enrolled in prospective trials (National Cancer Research Institute [NCRI] AML17 and AML19, n = 1357) to delineate the impact of baseline molecular and clinical features, postinduction MRD status, and treatment intensity on the outcome. FLT3-ITD (hazard ratio [HR], 1.28; 95% confidence interval [CI], 1.01-1.63), DNMT3A (HR, 1.65; 95% CI, 1.32-2.05), WT1 (HR, 1.74; 95% CI, 1.27-2.38), and non-ABD NPM1mut (HR, 1.64; 95% CI, 1.22-2.21) were independently associated with poorer overall survival (OS). These factors were also strongly associated with MRD positivity. For patients who achieved MRD negativity, these mutations (except FLT3-ITD) were associated with an increased cumulative incidence of relapse (CIR) and poorer OS. However, apart from the few patients with adverse cytogenetics, we could not identify any group of MRD-negative patients with a CIR >40% or with benefit from allograft in first remission. Intensified chemotherapy with the FLAG-Ida (fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin) regimen was associated with improved outcomes in all subgroups, with greater benefits observed in the high-risk molecular subgroups.

25 August 2018 in Addiction
Verified
Journal Article
Open access
PDF file
Craig GunnCraig Gunn
Craig Gunn
MMMarlou Mackus
Marlou Mackus
CGChris Griffin
Chris Griffin
MMMarcus R. Munafò
Marcus R. Munafò
SASally Adams
Sally Adams
Background and aims: Studies examining the next‐day cognitive effects of heavy alcohol consumption have produced mixed findings, which may reflect inconsistencies in definitions of ‘hangover’. Recent consensus has defined hangover as ‘mental and physical symptoms, experienced the day after a single episode of heavy drinking, starting when blood alcohol concentration (BAC) approaches zero’. In light of this, we aimed to review the literature systematically to evaluate and estimate mean effect sizes of the next‐day effects of heavy alcohol consumption on cognition.Methods: Embase, PubMed and PsycNET databases were searched between December 2016 and May 2018 using terms based on ‘alcohol’ and ‘hangover’. Studies of experimental designs which reported the next‐day cognitive effects of heavy alcohol consumption in a ‘hangover’ group with BAC < 0.02% were reviewed. A total of 805 articles were identified. Thirty‐nine full‐text articles were screened by two independent reviewers and 19 included in the systematic review; 11 articles provided sufficient data to be included in the meta‐analysis; 1163 participants across 19 studies conducted since 1970 were included in the analysis. Data for study design, hangover severity, BAC at testing and cognitive performance were extracted and effect estimates calculated.Results: The systematic review suggested that sustained attention and driving abilities were impaired during hangover. Mixed results were observed for: psychomotor skills, short‐ (STM) and long‐term memory (LTM) and divided attention. The meta‐analysis revealed evidence of impairments in STM [g = 0.64, 95% confidence interval (CI) = 0.15–1.13], LTM (Hedges’ g = 0.59, 95% CI = 0.01–1.17) sustained attention (g = 0.47, 95% CI = 0.07–0.87) and psychomotor speed (Hedges’ g = 0.66, 95% CI = 0.31–1.00) during alcohol hangover.Conclusion: The research literature suggests that alcohol hangovers may involve impaired cognitive functions and performance of everyday tasks such as driving.

9 May 2024 in Blood
Verified
Journal Article
Closed access
PDF file
JOJad Othman
Jad Othman
NPNicola Potter
Nicola Potter
AIAdam Ivey
Adam Ivey
JJJelena Jovanovic
Jelena Jovanovic
MRManohursingh Runglall
Manohursingh Runglall
NRNigel H. Russell
Nigel H. Russell
Selection of patients with NPM1-mutated acute myeloid leukemia (AML) for allogeneic transplant in first complete remission (CR1-allo) remains controversial because of a lack of robust data. Consequently, some centers consider baseline FLT3–internal tandem duplication (ITD) an indication for transplant, and others rely on measurable residual disease (MRD) status. Using prospective data from the United Kingdom National Cancer Research Institute AML17 and AML19 studies, we examined the impact of CR1-allo according to peripheral blood NPM1 MRD status measured by quantitative reverse transcription polymerase chain reaction after 2 courses of induction chemotherapy. Of 737 patients achieving remission, MRD was positive in 19%. CR1-allo was performed in 46% of MRD+ and 17% of MRD− patients. We observed significant heterogeneity of overall survival (OS) benefit from CR1-allo according to MRD status, with substantial OS advantage for MRD+ patients (3-year OS with CR1-allo vs without: 61% vs 24%; hazard ratio [HR], 0.39; 95% confidence interval [CI], 0.24-0.64; P < .001) but no benefit for MRD− patients (3-year OS with CR1-allo vs without: 79% vs 82%; HR, 0.82; 95% CI, 0.50-1.33; P = .4). Restricting analysis to patients with coexisting FLT3-ITD, again CR1-allo only improved OS for MRD+ patients (3-year OS, 45% vs 18%; compared with 83% vs 76% if MRD-); no interaction with FLT3 allelic ratio was observed. Postinduction molecular MRD reliably identifies those patients who benefit from allogeneic transplant in first remission. The AML17 and AML19 trials were registered at www.isrctn.com as #ISRCTN55675535 and #ISRCTN78449203, respectively.

1 December 2022 in Blood
Verified
Journal Article
Open access
PDF file
SLSun Loo
Sun Loo
RDRichard Dillon
Richard Dillon
AIAdam Ivey
Adam Ivey
NANatasha S. Anstee
Natasha S. Anstee
JOJad Othman
Jad Othman
Andrew H WeiAndrew H Wei
Andrew H Wei

Verified
Journal Article
Open access
PDF file
CAChris Alford
Chris Alford
CBCallum Broom
Callum Broom
HCHarriet Carver
Harriet Carver
SJSean Johnson
Sean Johnson
SLSam Lands
Sam Lands
Joris C VersterJoris C Verster
Joris C Verster
Driving is increasing across the world and road traffic accidents are a major cause of serious injuries and fatalities. The link between alcohol consumption and impaired driving has long been established and has led to legislation in many countries, with enforcement of legal limits based on blood alcohol concentration levels. Alcohol hangover research is an emerging field with a range of laboratory and naturalistic studies now clearly demonstrating the significant impairments that can result from hangover, even when alcohol levels are measured at or close to zero the day following a social drinking occasion. Driving is a commonplace activity but requires competency with a range of complex and potentially demanding tasks. Driving impaired can have serious consequences, including death and serious injury. There have been only limited alcohol hangover driving studies. The studies presented examined the consequences of alcohol hangover with a driving simulator contrasting a group with zero residual alcohol (N = 26) next day and another with residual alcohol (N = 26) assessed with breathalyzer in the morning before undertaking a 20 min commute to work. All participants completed a morning drive after a night without alcohol consumption and another after a night of social drinking. The driving scenarios were relatively demanding including traffic and pedestrians, traffic lights and other potential hazards in a mixed rural and urban journey. Subjective hangover and workload were assessed in addition to a range of driving performance variables, including divided attention, steering control and driving violations. Analyses contrasted driving in the no alcohol condition with the residual alcohol condition. The combined groups data (N = 52) was contrasted with the zero and residual alcohol groups. Significant contrasts were found for a range of driving measures, including divided attention, vehicle control, and driving violations as well as perceived workload. The pattern of impairment was broadly similar across both groups, indicating that whether or not residual alcohol was present, consistent driving impairment was seen. The relatively high number of significant variables may reflect the increased cognitive demand of the 20 min commute drive including busy and complex urban environments. This was also reflected in the significant increase in perceived workload recorded across the 6 dimensions of the National Aeronautics and Space Administration Task Load Index (NASA-TLX). Associations between subjective measures and driving performance with hangover suggested a potential lack of awareness of impairment, though were limited in number. The overall findings indicate that the levels of impairment seen reflect those seen with alcohol impaired driving, even when breath alcohol is zero.

9 January 2020 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Joris C VersterJoris C Verster
Joris C Verster
DKDarren Kruisselbrink
Darren Kruisselbrink
KSKarin A. Slot
Karin A. Slot
AAAikaterini Anogeianaki
Aikaterini Anogeianaki
SASally Adams
Sally Adams
ASAnn-Kathrin Stock
Ann-Kathrin Stock
The 2010 Alcohol Hangover Research Group consensus paper defined a cutoff blood alcohol concentration (BAC) of 0.11% as a toxicological threshold indicating that sufficient alcohol had been consumed to develop a hangover. The cutoff was based on previous research and applied mostly in studies comprising student samples. Previously, we showed that sensitivity to hangovers depends on (estimated) BAC during acute intoxication, with a greater percentage of drinkers reporting hangovers at higher BAC levels. However, a substantial number of participants also reported hangovers at comparatively lower BAC levels. This calls the suitability of the 0.11% threshold into question. Recent research has shown that subjective intoxication, i.e., the level of severity of reported drunkenness, and not BAC, is the most important determinant of hangover severity. Non-student samples often have a much lower alcohol intake compared to student samples, and overall BACs often remain below 0.11%. Despite these lower BACs, many non-student participants report having a hangover, especially when their subjective intoxication levels are high. This may be the case when alcohol consumption on the drinking occasion that results in a hangover significantly exceeds their “normal” drinking level, irrespective of whether they meet the 0.11% threshold in any of these conditions. Whereas consumers may have relative tolerance to the adverse effects at their “regular” drinking level, considerably higher alcohol intake—irrespective of the absolute amount—may consequentially result in a next-day hangover. Taken together, these findings suggest that the 0.11% threshold value as a criterion for having a hangover should be abandoned.